PYC Therapeutics Raises AU$146 million to Drive RNA Therapy Advancements

PYC Therapeutics (ASX: PYC) has completed its AU$146 million Entitlement Offer, securing funding to advance its pipeline of RNA-based therapies. The institutional component raised AU$91 million, with the remaining AU$55 million to be raised through the retail offering.

This funding will support the development of four first-in-class drug candidates, each with the potential to address significant unmet medical needs. With a proprietary drug delivery platform enhancing RNA therapy effectiveness, PYC is at the forefront of precision medicine innovation.

CEO Dr. Rohan Hockings highlighted the importance of this milestone, emphasizing that the funds will drive key human trial data readouts over the next 24 months. With strong investor support, PYC is well-positioned to accelerate its mission of transforming lives through groundbreaking genetic disease treatments.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com